falsefalse

Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 8

Looking Into the Future and at Unmet Needs in EGFRm NSCLC

,

Panelists discuss how medical professionals identify key unmet needs in EGFR-mutated non–small cell lung cancer (NSCLC) treatment, particularly in overcoming resistance. Challenges include addressing acquired resistance to targeted therapies, enhancing central nervous system penetration, managing toxicity, and developing novel agents or combinations to improve long-term outcomes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC
    EP. 2: FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach
    EP. 3: Clinical Factors to Consider When Choosing a Treatment Strategy
    EP. 4: Treatment Strategies to Manage AEs in EGFRm NSCLC
    EP. 5: The Multidisciplinary Team’s Role in EGFRm NSCLC Management
    EP. 6: Role of Rebiopsy at Disease Progression in EGFRm NSCLC
    EP. 7: Treatment Sequencing in Disease Progression in EGFRm NSCLC
    Now Viewing
    EP. 8: Looking Into the Future and at Unmet Needs in EGFRm NSCLC

    Video content above is prompted by the following:

    What do you see as the biggest unmet needs in EGFR-mutated NSCLC treatment, particularly in the resistance setting?

    Related Content:

    Critical Questions in Choosing EGFR-Targeted Therapies for NSCLCVideo SeriesClinicalInsights
    Genomic Assays in Breast Cancer: Key Differences, Clinical Utility, and Test Selection
    Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
    Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL
    x